New Four-in-One antibody takes on advanced breast cancer
NCT ID NCT05160545
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 36 times
Summary
This early-stage study tests a new drug called GNC-035 in people with advanced breast cancer that has spread or cannot be removed by surgery. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 36 adults will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dongguan People's Hospital
Dongguan, Guangdong, China
-
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, 510120, China
-
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, China
-
The Third Hospital of Changsha
Changsha, Hunan, China
-
West China Hospital，Sichuan University
Chengdu, Sichuan, China
-
ZhuJiang Hospital of Southern Medical University
Guangzhou, Guangdong, China
Conditions
Explore the condition pages connected to this study.